Cargando…
The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial
PURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the associa...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563600/ https://www.ncbi.nlm.nih.gov/pubmed/34523108 http://dx.doi.org/10.1007/s12630-021-02100-4 |
_version_ | 1784593438362042368 |
---|---|
author | Bartoszko, Justyna Callum, Jeannie Karkouti, Keyvan |
author_facet | Bartoszko, Justyna Callum, Jeannie Karkouti, Keyvan |
author_sort | Bartoszko, Justyna |
collection | PubMed |
description | PURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the association of comparable PCC or FP doses with transfusion and outcomes. METHODS: This was a post hoc analysis of a multicentre randomized trial comparing fibrinogen concentrate with cryoprecipitate (FIBRES trial) in bleeding cardiac surgical patients. This analysis included 415 patients who received only PCC (n = 72; 17%) or only FP (n = 343; 83%) for factor replacement. The main outcomes of interest were red blood cell (RBC) and platelet transfusion within 24 hr of cardiopulmonary bypass. Secondary outcomes included postoperative adverse events. Associations were examined by hierarchical generalized estimating equation models adjusted for demographic and surgical characteristics. RESULTS: The median [interquartile range (IQR)] PCC dose was 1,000 [1,000–2,000] units, while the median [IQR] FP dose was 4 [2–6] units. Each unit of FP was independently associated with increased adjusted odds of RBC (1.60; 95% confidence interval [CI], 1.36 to 1.87; P < 0.01) and platelet transfusion (1.40; 95% CI, 1.15 to 1.69; P < 0.01) while each 500 units of PCC was independently associated with reduced adjusted odds of RBC (0.67; 95% CI, 0.50 to 0.90; P < 0.01) and platelet transfusion (0.80; 95% CI, 0.70 to 0.92; P < 0.01). Adverse event rates were comparable. CONCLUSIONS: In cardiac surgical patients with post-cardiopulmonary bypass bleeding, PCC use was associated with lower RBC and platelet transfusion than FP use was. Prospective, randomized clinical trials comparing FP with PCC in this setting are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12630-021-02100-4. |
format | Online Article Text |
id | pubmed-8563600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85636002021-11-04 The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial Bartoszko, Justyna Callum, Jeannie Karkouti, Keyvan Can J Anaesth Reports of Original Investigations PURPOSE: The mainstay of therapy for coagulation factor deficiency in cardiac surgical patients is frozen plasma (FP); however, prothrombin complex concentrates (PCCs) may offer logistical and safety advantages. As there is limited comparative evidence, we conducted this study to explore the association of comparable PCC or FP doses with transfusion and outcomes. METHODS: This was a post hoc analysis of a multicentre randomized trial comparing fibrinogen concentrate with cryoprecipitate (FIBRES trial) in bleeding cardiac surgical patients. This analysis included 415 patients who received only PCC (n = 72; 17%) or only FP (n = 343; 83%) for factor replacement. The main outcomes of interest were red blood cell (RBC) and platelet transfusion within 24 hr of cardiopulmonary bypass. Secondary outcomes included postoperative adverse events. Associations were examined by hierarchical generalized estimating equation models adjusted for demographic and surgical characteristics. RESULTS: The median [interquartile range (IQR)] PCC dose was 1,000 [1,000–2,000] units, while the median [IQR] FP dose was 4 [2–6] units. Each unit of FP was independently associated with increased adjusted odds of RBC (1.60; 95% confidence interval [CI], 1.36 to 1.87; P < 0.01) and platelet transfusion (1.40; 95% CI, 1.15 to 1.69; P < 0.01) while each 500 units of PCC was independently associated with reduced adjusted odds of RBC (0.67; 95% CI, 0.50 to 0.90; P < 0.01) and platelet transfusion (0.80; 95% CI, 0.70 to 0.92; P < 0.01). Adverse event rates were comparable. CONCLUSIONS: In cardiac surgical patients with post-cardiopulmonary bypass bleeding, PCC use was associated with lower RBC and platelet transfusion than FP use was. Prospective, randomized clinical trials comparing FP with PCC in this setting are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12630-021-02100-4. Springer International Publishing 2021-09-14 2021 /pmc/articles/PMC8563600/ /pubmed/34523108 http://dx.doi.org/10.1007/s12630-021-02100-4 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Reports of Original Investigations Bartoszko, Justyna Callum, Jeannie Karkouti, Keyvan The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial |
title | The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial |
title_full | The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial |
title_fullStr | The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial |
title_full_unstemmed | The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial |
title_short | The association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the FIBRES randomized controlled trial |
title_sort | association of prothrombin complex concentrates with postoperative outcomes in cardiac surgery: an observational substudy of the fibres randomized controlled trial |
topic | Reports of Original Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563600/ https://www.ncbi.nlm.nih.gov/pubmed/34523108 http://dx.doi.org/10.1007/s12630-021-02100-4 |
work_keys_str_mv | AT bartoszkojustyna theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT callumjeannie theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT karkoutikeyvan theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT theassociationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT bartoszkojustyna associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT callumjeannie associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT karkoutikeyvan associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial AT associationofprothrombincomplexconcentrateswithpostoperativeoutcomesincardiacsurgeryanobservationalsubstudyofthefibresrandomizedcontrolledtrial |